It is now accepted that body fat is also regulated by this system. The central nervous system controls many biological parameters in the body to keep different systems at a balance including hormones, fluid, and food intake and energy expenditure. However, the response to treatment is governed by biology and not external motivation. These figures have made us aware on the complexity of treating this disease and the importance of personalizing treatments to obtain better success. Once overweight or obesity occurs, the probability of attaining a normal weight with lifestyle and pharmacotherapy becomes 1 in 210 for men and 1 in 124 for women, and 1 in 1,290 for men and 1 in 677 for women with morbid obesity ( 4). Only 1 in 8 men and 1 in 7 women are able to lose 5% of their weight ( 4) with even fewer achieving the 10% weight loss target required to substantially improve type 2 diabetes ( 5). Lifestyle interventions are used as the first line therapy towards achieving moderate weight loss targets. Patients with prediabetes or type 2 diabetes are asked to lose weight to control the progression of the disease. Lorcaserin is an FDA approved selective agonist for 5-hydroxytryptamine 2C serotonin receptors (5-HT2C) for the management of obesity as it reduces the symptoms of obesity (excess hunger and lack of satiety) via actions on the subcortical areas of the brain which regulate appetite ( 2, 3). The CAMELLIA-TIMI 61 in The Lancet shed light on the use of lorcaserin for the prevention and remission of type 2 diabetes for people with overweight and obesity ( 1). While the rates of those diseases are reaching dangerous levels globally, effective non-invasive remission methods of the diseases are still lacking. Type 2 diabetes and its precursor ‘prediabetes’ are common complications of obesity. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Email: This is an invited Editorial commissioned by the Section Editor Kaiping Zhang (AME College, AME Group, China).Ĭomment on: Bohula EA, Scirica BM, Inzucchi SE, et al. Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland. Policy of Dealing with Allegations of Research MisconductĬorrespondence to: Professor Carel W.Policy of Screening for Plagiarism Process.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |